Imaging Techniques for Brain Tumor

Overseen By Eileen Chang

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Weill Medical College of Cornell University

Disqualifiers: Pregnant, breastfeeding, claustrophobia

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

30 Participants Needed

Trial Summary

What is the purpose of this trial?

This is a pilot study to assess a new methodology developed for High Grade Glioma (HGG). FMISO PET (Fluoromisonidazole-PET) allows researchers to study whether tumor cells lack oxygen (hypoxia). FLT PET (Fluorodeoxythymidine-PET) allows researchers to study the increase in the number of cells as a result of cell growth and cell division (proliferation). Tumors that have low oxygen levels and/or are dividing fast shall resist to standard cancer treatment. The study will compare FMISO PET and FLT PET imaging techniques with molecular biomarkers of hypoxia, angiogenesis, and cellular proliferation in tissue. proliferation).This information could help researchers develop new treatment techniques to better treat cancer.

Research Team

Sadek Nehmeh, PhD

Principal Investigator

Weill Medical College of Cornell University

Eligibility Criteria

This trial is for adults over 18 suspected to have High-Grade Glioma (HGG) based on clinical assessments and MRI results. It's not suitable for pregnant or breastfeeding individuals, or those who can't undergo PET scans due to conditions like claustrophobia.

Inclusion Criteria

My diagnosis of a high-grade glioma is based on clinical exams and MRI results.

I am 18 years old or older.

Exclusion Criteria

Pregnant or breastfeeding

You have a condition that makes it unsafe for you to have a PET scan, like claustrophobia.

Treatment Details

Interventions

• 18F-FLT PET
• 18F-FMISO PET

Trial Overview The study tests two PET imaging techniques: FMISO PET, which checks if tumor cells are lacking oxygen, and FLT PET, which examines cell growth. These will be compared with tissue biomarkers of hypoxia and proliferation to improve cancer treatment strategies.

Participant Groups

Group I: High Grade Glioma (HGG) Experimental Treatment 2 Interventions

Thirty newly diagnosed treatment-naïve subjects with suspected HGG based on clinical presentation and MRI findings and undergoing surgical planning will be accrued in this study.

Who Is Running the Clinical Trial?

Weill Medical College of Cornell University

Lead Sponsor

Trials

1,103

Recruited

1,157,000+

William Rhodes Center for Glioblastoma

Collaborator

Trials

1

Recruited

30+